Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Overview of attention for article published in Cancer Nanotechnology, July 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#1 of 222)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results eIND application submission for TTX-MC1…

eIND application submission for TTX-MC138 anticipated in H1 2022 BOSTON–(BUSINESS WIRE)–TransCode Therapeutics, Inc.

- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated…

eIND application submission for TTX-MC138 anticipated in H1 2022 BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.